Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02399137 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

A Phase 2 study of Pancreatic Cancer, sponsored by Merrimack Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT02399137 is a Phase 2 study of Pancreatic Cancer that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 88 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02399137, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Merrimack Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG Placebo
  • DRUG Nab-Paclitaxel
  • DRUG Gemcitabine
  • DRUG MM-141

Study Locations (20)

California

  • Pacific Cancer Medical Center, Inc. - Anaheim
  • St. Jude Heritage Healthcare - Fullerton
  • UCLA School of Medicine - Los Angeles
  • Cancer Care Assoc Med Grp - Redondo Beach
  • UCSF Cancer Center - San Francisco
  • Sansum Clinic - Santa Barbara
  • Central Coast Med Onc Corp - Santa Maria

Illinois

  • Northwestern University - Chicago
  • University of Illinois at Chicago - Chicago
  • Illinois Cancer Specialists - Chicago
  • Oncology Specialists, S.C. - Park Ridge
  • Midwest Regional Medical Cntr - Zion

Florida

  • Baptist Health Med Gr Onc, LLC - Miami
  • Florida Cancer AffiliatesOcala - Ocala
  • Memorial Regional Hospital - Pembroke Pines

Arizona

  • Banner MD Anderson Cancer Ctr. - Gilbert

Colorado

  • Rocky Mountain Cancer Centers - Aurora

Georgia

  • Cancer Treatment Centers of America-Georgia - Newnan

Iowa

  • Nylen Cancer Center - Sioux City

Louisiana

  • Cancer Center of Acadiana Research Department - Lafayette

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2015-05
Est. Completion 2018-08
Phase Phase 2

Sponsor

Merrimack Pharmaceuticals

22 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02399137

The ClinicalTrials.gov registry entry for NCT02399137 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT02399137 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT02399137 about?

NCT02399137 is a clinical study titled "A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer". The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-...

What is the current status of trial NCT02399137?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2015-05. Estimated completion is 2018-08.

What conditions does trial NCT02399137 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT02399137?

The interventions under investigation include: Placebo (DRUG), Nab-Paclitaxel (DRUG), Gemcitabine (DRUG), MM-141 (DRUG).

Who is sponsoring clinical trial NCT02399137?

This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02399137 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.